



Authorisation to initiate the MUCOBOOST clinical trial - first-in-human with LVT-001, nasal vaccine against COVID-19 developed by Lovaltech

LVT-001 is a vaccine delivered as a nasal spray that aims to provide full protection against all COVID-19 variants. By blocking the transmission, the goal is to reduce human-to-human contagion and viral circulation.

The clinical trial phase I will start by the end of April 2025 at Centre d'Investigation Clinique (CIC) CHRU de Tours and CIC Cochin-Paster (Paris). The objective is to evaluate both the tolerance and immune response in healthy volunteers to determine the recommended dose for Phase II. This dose escalation study requires the participation of 36 volunteers. 3 dose levels of the nasal vaccine will be tested on 3 groups. The first group will start with the lowest dose, and dose escalation rules will then be applied. Volunteers will undergo a 12-months follow-up. Preliminary results are expected in the fall of 2025.

The clinical trial phase II is planned for early 2026. The objective will be to validate the superiority in inducing a local protective immunity versus mRNA vaccine, hence providing a superior competitive advantage against contagiousness. 202 healthy volunteers will be enrolled over 5 clinical centres (Tours, Saint-Etienne, Lyon, Cochin, and Dijon).

This multicentre clinical trial is co-sponsored by the CHRU de Tours and ANRS MIE; an unprecedented alliance between research centres and reference hospitals, ensuring a rigorous scientific framework and optimal evaluation conditions.

About Lovaltech

Lovaltech is a cutting-edge biotechnology company dedicated to developing innovative health solutions to address global health emergencies. With a strong focus on breakthrough innovation and state-of-the-art scientific expertise, Lovaltech strives to improve the quality of life for people worldwide.

Lovaltech aims to become a global leader in vaccination through its proprietary vaccine platform, to accelerate the development of new protein-based nasal vaccines to target infectious diseases that are currently under-addressed or not covered by existing

vaccines. Additionally, the company is committed to combating future pandemics within a OneHealth framework.

<https://www.lovaltechnology.com>

Contact

Lovaltech:

Patrick Barillot, CEO, patrick.barillot@lovaltechnology.com

Co-Sponsors:

CHRU de Tours / ANRS MIE

Scientific Coordinator:

Professor Isabelle DIMIER-POISSON, University of Tours

Lead Investigator:

Dr. Zoha MAAKAROUN-VERMESSE, CHRU de Tours

Co-Lead Investigator:

Professor Odile LAUNAY, Cochin Pasteur CIC

